Giovanni Caforio (Christopher Goodney/Bloomberg via Getty Images)

Bris­tol My­ers of­fers a big pre­mi­um to reel in MyoKar­dia's car­dio pipeline with a $13B buy­out

Five months af­ter MyoKar­dia $MYOK swept its late-stage piv­otal on its lead heart drug — high­light­ing its suc­cess with a pre­ci­sion med ap­proach to car­di­ol­o­gy — Bris­tol My­ers Squibb is step­ping up with a $13.1 bil­lion buy­out tied to a big pre­mi­um.

Bris­tol My­ers is pay­ing $225 a share — a 61% pre­mi­um — to get its hands on the car­dio play­er, high­light­ing its in­ter­est in mava­camten, where ex­ecs see a first-in-class role treat­ing ob­struc­tive hy­per­trophic car­diomy­opa­thy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA